A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Exclusion Criteria

• •Participants who have a diagnosis of type 1 diabetes
• •Participants who have previously been treated with any other glucagon-like peptide-1 (GLP-1) analog within the 3 months before screening
• •Participants who are currently taking insulin or have had previous insulin treatment within the 3 months before screening
• •Participants who have obvious clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis, or acute pancreatitis at screening, as determined by the investigator. Participants who have a serum amylase concentration ≥3 times the upper limit of the reference range and/or a serum lipase concentration ≥2 times the upper limit of the reference range, as determined by the central laboratory at screening
• •Participants who have self or family history of medullary C-cell hyperplasia, focal hyperplasia, or medullary thyroid carcinoma (MTC)